In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Angiodynamic Inc (NASDAQ: ANGO) closed at $9.86 down -1.89% from its previous closing price of $10.05. In other words, the price has decreased by -$1.89 from its previous closing price. On the day, 0.95 million shares were traded. ANGO stock price reached its highest trading level at $10.21 during the session, while it also had its lowest trading level at $9.835.
Ratios:
For a deeper understanding of Angiodynamic Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 2.24. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on July 16, 2025, initiated with a Buy rating and assigned the stock a target price of $24.
On April 05, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
On September 25, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.H.C. Wainwright initiated its Buy rating on September 25, 2023, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 21 ’25 when Weiss Lawrence T bought 10,000 shares for $11.81 per share. The transaction valued at 118,100 led to the insider holds 93,597 shares of the business.
Trowbridge Stephen A bought 890 shares of ANGO for $9,932 on Oct 13 ’25. The EVP and CFO now owns 256,629 shares after completing the transaction at $11.16 per share. On Oct 09 ’25, another insider, Clemmer James C, who serves as the President and CEO of the company, bought 10,000 shares for $11.15 each. As a result, the insider paid 111,500 and bolstered with 882,529 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANGO now has a Market Capitalization of 406403392 and an Enterprise Value of 376555424. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.35 while its Price-to-Book (P/B) ratio in mrq is 2.32. Its current Enterprise Value per Revenue stands at 1.225 whereas that against EBITDA is -2510.37.
Stock Price History:
The Beta on a monthly basis for ANGO is 0.52, which has changed by -0.20866776 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, ANGO has reached a high of $13.99, while it has fallen to a 52-week low of $8.27. The 50-Day Moving Average of the stock is -21.24%, while the 200-Day Moving Average is calculated to be -7.04%.
Shares Statistics:
For the past three months, ANGO has traded an average of 543.55K shares per day and 1017670 over the past ten days. A total of 41.57M shares are outstanding, with a floating share count of 38.87M. Insiders hold about 5.70% of the company’s shares, while institutions hold 93.19% stake in the company. Shares short for ANGO as of 1765756800 were 2121460 with a Short Ratio of 3.90, compared to 1763078400 on 2174768. Therefore, it implies a Short% of Shares Outstanding of 2121460 and a Short% of Float of 5.48.
Earnings Estimates
The stock of Angiodynamic Inc (ANGO) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.06 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.26 and -$0.33 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.11, with 3.0 analysts recommending between -$0.08 and -$0.13.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $76.77M this quarter.It ranges from a high estimate of $78M to a low estimate of $75.3M. As of. The current estimate, Angiodynamic Inc’s year-ago sales were $72MFor the next quarter, 3 analysts are estimating revenue of $80.97M. There is a high estimate of $82.5M for the next quarter, whereas the lowest estimate is $79.9M.
A total of 3 analysts have provided revenue estimates for ANGO’s current fiscal year. The highest revenue estimate was $313.64M, while the lowest revenue estimate was $312M, resulting in an average revenue estimate of $312.88M. In the same quarter a year ago, actual revenue was $292.5MBased on 3 analysts’ estimates, the company’s revenue will be $328.33M in the next fiscal year. The high estimate is $330M and the low estimate is $326M.
